Dermatology

Host: Raj Chovatiya, MD, PhD

In light of the Maui Derm 2025 conference, Dr. Raj Chovatiya is here to discuss the most significant updates in the dermatology field that helped define 2024. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

Host: Raj Chovatiya, MD, PhD

How should we approach caring for undifferentiated eczema patients who didn’t have eczema as a child, who doesn’t have atopic co-morbidities, and isn’t flexural? Here to give a quick overview of his session at the Maui Derm 2025 conference that sought to help answer this question is Dr. Raj Chovatiya. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

Host: Jennifer Caudle, DO

Guest: Steven R. Feldman, MD, PhD

The American Academy of Dermatology recently updated their guidelines regarding the treatment of moderate-to-severe atopic dermatitis to expand the recommended use of systemic therapies like biologics and JAK inhibitors. To help ensure our approach is up to date, Dr. Jennifer Caudle speaks with Dr. Steven Feldman about the new guidelines and how we can implement them into clinical practice. Dr. Feldman is a Professor of Dermatology, Pathology, Social Sciences and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Host: Raj Chovatiya, MD, PhD

Guest: Christopher Bunick, MD, PhD, FAAD

The American Academy of Dermatology recently updated the treatment guidelines for atopic dermatitis to include the latest systemic therapies, like biologics and JAK inhibitors. Since these new standards of care could offer improved outcomes for our patients with atopic dermatitis, Dr. Raj Chovatiya speaks with Dr. Christopher Bunick about what the new guidelines recommend and how we can incorporate them into clinical practice. Dr. Bunick is an Associate Professor of Dermatology at the Yale School of Medicine.

Guest: Jennifer Murase, MD

Pregnancy can trigger atopic dermatitis, with immune system shifts commonly contributing to skin issues. Dr. Jennifer Murase joins the program to explain the mechanisms behind pregnancy dermatoses and best practices for caring for patients, which she presented on at the 2024 Elevate Derm Conference. Dr. Murase is the Founder and Chair of the American Academy of Dermatology Women’s Health Expert Resource Group.

Guest: Jörg Latus, MD

Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These symptoms have the potential to significantly diminish patients’ quality of life by affecting sleep, mental health, and more. This activity reviews best practices for communicating with patients about symptoms and how to use shared decision-making strategies to develop personalized CKD-aP treatment plans.

Guest: Scott Gottlieb, MD

Host: Charles Turck, PharmD, BCPS, BCCCP

Patients 50+ with moderate-to-severe plaque psoriasis face adherence challenges, increased risk of comorbidities, and insurance transitions from commercial to Medicare. To learn more about how ILUMYA® (tildrakizumab-asmn) helps address the specific treatment needs of these patients, join Dr. Charles Turck as he speaks with Dr. Scott Gottlieb, a physician at Schweiger Dermatology Group in Exton, Pennsylvania.

Host: James Burton, DM, FRCP

Guest: Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS

Patients with chronic kidney disease may be experiencing severe itch, known as CKD-associated pruritus (CKD-aP). Itching and related symptoms, such as reduced sleep and depression, may be causing a significant negative impact on their quality of life. Join our experts as they use real-world patient cases to illustrate how to identify and treat itch, provide relief from itch-related symptoms, and improve quality of life in your patients with CKD-aP.

Host: Stefan H. Jacobson, MD, PhD

Guest: Carlos Narváez Mejía, MD

Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Steven R. Feldman, MD, PhD

Patients’ adherence to psoriasis treatment, especially topical treatment, is often abysmal due to a variety of challenges and factors. That’s why Dr. Charles Turck speaks with Dr. Steven Feldman about these common challenges and how we can overcome them to improve adherence among our psoriasis patients. Dr. Feldman is a Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston Salem, North Carolina.